Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immunome, Inc. stock logo
IMNM
Immunome
$8.89
+4.0%
$8.66
$5.15
$16.81
$743.96M1.92893,880 shs1.58 million shs
ProKidney Corp. stock logo
PROK
ProKidney
$4.34
+16.4%
$0.89
$0.46
$7.13
$1.09B1.262.91 million shs209.67 million shs
uniQure N.V. stock logo
QURE
uniQure
$14.87
+3.0%
$14.56
$4.45
$19.18
$790.96M0.081.76 million shs1.61 million shs
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$9.24
+5.6%
$10.21
$8.58
$25.07
$752.91M0.71.85 million shs3.13 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immunome, Inc. stock logo
IMNM
Immunome
+3.98%+3.01%-4.10%+43.39%-28.88%
ProKidney Corp. stock logo
PROK
ProKidney
+16.35%+649.96%+342.86%+607.42%+73.60%
uniQure N.V. stock logo
QURE
uniQure
+2.98%+4.13%-12.01%+73.51%+122.94%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
+5.60%+2.67%-16.68%-12.17%-59.06%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Immunome, Inc. stock logo
IMNM
Immunome
1.9923 of 5 stars
3.52.00.00.01.12.50.0
ProKidney Corp. stock logo
PROK
ProKidney
1.5474 of 5 stars
2.10.00.00.02.94.20.6
uniQure N.V. stock logo
QURE
uniQure
1.8292 of 5 stars
3.51.00.00.00.62.50.6
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
3.295 of 5 stars
3.51.00.04.42.00.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Immunome, Inc. stock logo
IMNM
Immunome
3.00
Buy$23.33162.47% Upside
ProKidney Corp. stock logo
PROK
ProKidney
2.25
Hold$5.3322.89% Upside
uniQure N.V. stock logo
QURE
uniQure
2.91
Moderate Buy$37.82154.33% Upside
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
2.90
Moderate Buy$35.80287.45% Upside

Current Analyst Ratings Breakdown

Latest PROK, SNDX, IMNM, and QURE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
ProKidney Corp. stock logo
PROK
ProKidney
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$6.00 ➝ $9.00
6/30/2025
ProKidney Corp. stock logo
PROK
ProKidney
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underperform$3.00 ➝ $1.00
5/30/2025
uniQure N.V. stock logo
QURE
uniQure
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00
5/29/2025
uniQure N.V. stock logo
QURE
uniQure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$70.00
5/19/2025
uniQure N.V. stock logo
QURE
uniQure
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/13/2025
Immunome, Inc. stock logo
IMNM
Immunome
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$33.00 ➝ $21.00
5/12/2025
uniQure N.V. stock logo
QURE
uniQure
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
5/12/2025
uniQure N.V. stock logo
QURE
uniQure
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
5/6/2025
uniQure N.V. stock logo
QURE
uniQure
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
5/6/2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$16.00 ➝ $17.00
5/6/2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Immunome, Inc. stock logo
IMNM
Immunome
$9.04M85.57N/AN/A$2.27 per share3.92
ProKidney Corp. stock logo
PROK
ProKidney
$80K15,878.98N/AN/A($3.41) per share-1.27
uniQure N.V. stock logo
QURE
uniQure
$27.12M30.04N/AN/A($0.14) per share-106.21
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$23.68M33.58N/AN/A$3.38 per share2.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Immunome, Inc. stock logo
IMNM
Immunome
-$292.96M-$3.18N/AN/AN/A-1,875.21%-71.65%-60.36%8/11/2025 (Estimated)
ProKidney Corp. stock logo
PROK
ProKidney
-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)
uniQure N.V. stock logo
QURE
uniQure
-$239.56M-$4.39N/AN/AN/A-1,077.05%-483.87%-34.28%8/7/2025 (Estimated)
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$318.76M-$3.86N/AN/AN/A-757.53%-101.60%-58.41%8/7/2025 (Estimated)

Latest PROK, SNDX, IMNM, and QURE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
uniQure N.V. stock logo
QURE
uniQure
-$0.89N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$0.99N/AN/AN/AN/AN/A
5/12/2025Q1 2025
Immunome, Inc. stock logo
IMNM
Immunome
-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million
5/12/2025Q1 2025
ProKidney Corp. stock logo
PROK
ProKidney
-$0.16-$0.13+$0.03-$0.13N/A$0.23 million
5/9/2025Q1 2025
uniQure N.V. stock logo
QURE
uniQure
-$1.07-$0.82+$0.25-$0.82$5.93 million$1.57 million
5/5/2025Q1 2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Immunome, Inc. stock logo
IMNM
Immunome
N/AN/AN/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
N/AN/AN/AN/AN/A
uniQure N.V. stock logo
QURE
uniQure
N/AN/AN/AN/AN/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Immunome, Inc. stock logo
IMNM
Immunome
N/A
10.49
10.49
ProKidney Corp. stock logo
PROK
ProKidney
N/A
10.96
10.96
uniQure N.V. stock logo
QURE
uniQure
1.53
11.99
11.99
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
1.53
5.80
5.75

Institutional Ownership

CompanyInstitutional Ownership
Immunome, Inc. stock logo
IMNM
Immunome
44.58%
ProKidney Corp. stock logo
PROK
ProKidney
51.59%
uniQure N.V. stock logo
QURE
uniQure
78.83%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Immunome, Inc. stock logo
IMNM
Immunome
8.60%
ProKidney Corp. stock logo
PROK
ProKidney
41.49%
uniQure N.V. stock logo
QURE
uniQure
4.79%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Immunome, Inc. stock logo
IMNM
Immunome
4087.01 million79.53 millionOptionable
ProKidney Corp. stock logo
PROK
ProKidney
3292.70 million171.26 millionOptionable
uniQure N.V. stock logo
QURE
uniQure
50054.78 million52.15 millionOptionable
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
11086.05 million82.52 millionOptionable

Recent News About These Companies

Syndax Pharmaceuticals, Inc. (SNDX) - Yahoo Finance
SNDX Syndax Pharmaceuticals, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Immunome stock logo

Immunome NASDAQ:IMNM

$8.89 +0.34 (+3.98%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$8.88 -0.02 (-0.17%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

ProKidney stock logo

ProKidney NASDAQ:PROK

$4.34 +0.61 (+16.35%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$4.92 +0.59 (+13.48%)
As of 05:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

uniQure stock logo

uniQure NASDAQ:QURE

$14.87 +0.43 (+2.98%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$15.18 +0.31 (+2.11%)
As of 05:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Syndax Pharmaceuticals stock logo

Syndax Pharmaceuticals NASDAQ:SNDX

$9.24 +0.49 (+5.60%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$9.24 -0.01 (-0.05%)
As of 07/9/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.